Galati G, Rampa L, Vespasiani-Gentilucci U, Marino M, Pisani F, Cota C, Guidi A, Picardi A. Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. World J Hepatol 2016; 8(29): 1244-1250 [PMID: 27803769 DOI: 10.4254/wjh.v8.i29.1244]
Corresponding Author of This Article
Giovanni Galati, MD, Unit of Internal Medicine and Hepatology, Department of Medicine, Università Campus Bio-Medico di Roma, via Álvaro del Portillo 21, 00128 Rome, Italy. g.galati@unicampus.it
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Oct 18, 2016; 8(29): 1244-1250 Published online Oct 18, 2016. doi: 10.4254/wjh.v8.i29.1244
Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy
Giovanni Galati, Lorenzo Rampa, Umberto Vespasiani-Gentilucci, Mirella Marino, Francesco Pisani, Carlo Cota, Alessandro Guidi, Antonio Picardi
Giovanni Galati, Lorenzo Rampa, Umberto Vespasiani-Gentilucci, Alessandro Guidi, Antonio Picardi, Unit of Internal Medicine and Hepatology, Department of Medicine, Università Campus Bio-Medico di Roma, 00128 Rome, Italy
Mirella Marino, Department of Pathology, Regina Elena National Cancer Institute, 00144 Rome, Italy
Francesco Pisani, Hematology and Stem Cell Transplant Unit, Regina Elena National Cancer Institute, 00144 Rome, Italy
Carlo Cota, Dermopahology Unit, San Gallicano Dermatological Institute, IRCCS, 00144 Rome, Italy
Author contributions: All the authors contributed equally to the conception and design of the article.
Institutional review board statement: This case report was exempt from the Institutional Review Board standards at University of Campus Bio Medico of Rome.
Informed consent statement: The patient involved in this clinical case gave her written informed consent authorizing use and disclosure of her protected health information.
Conflict-of-interest statement: All the authors have no conflicts of interests to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Giovanni Galati, MD, Unit of Internal Medicine and Hepatology, Department of Medicine, Università Campus Bio-Medico di Roma, via Álvaro del Portillo 21, 00128 Rome, Italy. g.galati@unicampus.it
Telephone: +39-062-25411446 Fax: +39-062-25411944
Received: March 24, 2016 Peer-review started: March 24, 2016 First decision: June 12, 2016 Revised: June 25, 2016 Accepted: August 15, 2016 Article in press: August 16, 2016 Published online: October 18, 2016
Abstract
B cells lymphoma is one of the most challenging extra-hepatic manifestations of hepatitis C virus (HCV). Recently, a new kind of B-cell lymphoma, named double-hit B (DHL), was characterized with an aggressive clinical course whereas a potential association with HCV was not investigated. The new antiviral direct agents (DAAs) against HCV are effective and curative in the majority of HCV infections. We report the first case, to our knowledge, of DHL and HCV-infection successfully treated by new DAAs. According to our experience, a DHL must be suspected in case of HCV-related lymphoma, and an early diagnosis could direct towards a different hematological management because a worse prognosis might be expected. A possible effect of DAAs on DHL regression should be investigated, but eradicating HCV would avoid life-threatening reactivation of viral hepatitis during pharmacological immunosuppression in onco-haematological diseases.
Core tip: B cells lymphoma is one of the most challenging extra-hepatic manifestations of hepatitis C virus. Recently, a new kind of B-cell lymphoma, named Double-hit B, was characterized with an aggressive clinical course. This is the first case described in literature of double hit lymphoma with co-existing chronic hepatitis C, successfully treated by new direct antiviral therapies. This case suggests a potential favorable effect of the new antiviral therapies on double hit lymphoma regression.
